Compare Stocks

→ World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADMP Adamis Pharmaceuticals		$1.28	$0.75 ▼ $26.18	$7.26M	1.27	811,695 shs	119,800 shs
MACK Merrimack Pharmaceuticals	$14.71	$14.71	$11.53 ▼ $15.89	$213.74M	1.43	110,280 shs	43,954 shs
OPNT Opiant Pharmaceuticals		$20.58	$7.34 ▼ $29.25	$108.83M	0.84	77,920 shs	562,700 shs
SLS SELLAS Life Sciences Group	$1.52 -1.3%	$1.18	$0.50 ▼ $1.91	$85.53M	2.35	1.46 million shs	546,600 shs

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADMP Adamis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	-87.23%
MACK Merrimack Pharmaceuticals	-0.14%	+0.20%	-0.14%	+10.60%	+21.57%
OPNT Opiant Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
SLS SELLAS Life Sciences Group	-5.52%	+9.22%	+48.08%	+203.81%	+10.79%

Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)

Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.

Click here for your free guide

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OPNT Opiant Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	0.5763 of 5 stars	3.5	1.0	0.0	0.0	1.1	0.0	0.0

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A
OPNT Opiant Pharmaceuticals	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	3.00	Buy	$3.00	97.37% Upside

Current Analyst Ratings

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADMP Adamis Pharmaceuticals	$4.76M	0.00	N/A	N/A	($1.26) per share	0.00
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	$1.31 per share	N/A
OPNT Opiant Pharmaceuticals	$47.78M	0.00	N/A	24.75	$9.92 per share	0.00
SLS SELLAS Life Sciences Group	$1M	85.53	N/A	N/A	($0.25) per share	-6.08

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADMP Adamis Pharmaceuticals	-$26.48M	N/A	0.00	N/A	N/A	-502.73%	-420.53%	-256.87%	N/A
MACK Merrimack Pharmaceuticals	-$1.18M	-$0.08	N/A	∞	N/A	N/A	-6.24%	-6.09%	5/2/2024 (Estimated)
OPNT Opiant Pharmaceuticals	$3.01M	-$6.56	N/A	N/A	N/A	-147.90%	-97.03%	-59.66%	N/A
SLS SELLAS Life Sciences Group	-$37.34M	-$1.36	N/A	∞	N/A	N/A	-2,405.54%	-241.00%	5/9/2024 (Estimated)

Latest ADMP, SLS, MACK, and OPNT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/28/2024	Q4 2023	SLS SELLAS Life Sciences Group	N/A	-$0.25	-$0.25	-$0.25	N/A	N/A
3/7/2024	Q4 2023	MACK Merrimack Pharmaceuticals	N/A	-$0.01	-$0.01	-$0.01	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADMP Adamis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MACK Merrimack Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OPNT Opiant Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADMP Adamis Pharmaceuticals	N/A	0.23	0.19
MACK Merrimack Pharmaceuticals	N/A	43.50	43.50
OPNT Opiant Pharmaceuticals	0.60	5.48	5.48
SLS SELLAS Life Sciences Group	N/A	0.23	0.23

Ownership

Institutional Ownership

Company	Institutional Ownership
ADMP Adamis Pharmaceuticals	38.55%
MACK Merrimack Pharmaceuticals	63.97%
OPNT Opiant Pharmaceuticals	42.39%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
ADMP Adamis Pharmaceuticals	1.30%
MACK Merrimack Pharmaceuticals	28.87%
OPNT Opiant Pharmaceuticals	25.15%
SLS SELLAS Life Sciences Group	1.60%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADMP Adamis Pharmaceuticals	11	9.36 million	9.24 million	Optionable
MACK Merrimack Pharmaceuticals	426	14.53 million	10.34 million	Optionable
OPNT Opiant Pharmaceuticals	37	5.27 million	3.87 million	Not Optionable
SLS SELLAS Life Sciences Group	17	56.27 million	55.37 million	Not Optionable

ADMP, SLS, MACK, and OPNT Headlines

Source	Headline
	Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout seekingalpha.com - April 19 at 3:11 PM
	Seligman Launches a New Health Care Fund institutionalinvestor.com - March 28 at 7:32 PM
	SELLAS Life Sciences Group files for $200M mixed shelf msn.com - March 28 at 7:32 PM
	SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update globenewswire.com - March 28 at 4:05 PM
	Buy Rating for SELLAS Life Sciences Amid Positive AML Study Results and Strengthened Financials markets.businessinsider.com - March 27 at 10:54 PM
	SELLAS Phase 2a Study Of SLS009 In R/r AML Positive; Updates Phase 3 REGAL Study markets.businessinsider.com - March 26 at 10:33 AM
	SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study globenewswire.com - March 26 at 7:35 AM
	SELLAS Life Sciences Group Inc. wsj.com - March 21 at 3:15 PM
	SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules globenewswire.com - March 19 at 4:05 PM
	SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET globenewswire.com - March 19 at 8:47 AM
	Sellas Life Sciences Shares Drop 31% After Direct Offering Prices marketwatch.com - March 16 at 2:16 PM
	Geron, Graphite Bio, Immuneering among healthcare movers msn.com - March 15 at 10:20 AM
	SELLAS Life Sciences looks to raise $20M in a direct offering msn.com - March 15 at 10:20 AM
	Sellas Announces $20 Mln Registered Direct Offering, Concurrent Private Placement markets.businessinsider.com - March 15 at 10:20 AM
	SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules finance.yahoo.com - March 15 at 9:14 AM
	SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules globenewswire.com - March 15 at 9:00 AM
	Aadi Bioscience Q4 2023 Earnings Preview seekingalpha.com - March 12 at 12:49 PM
	Sellas Life Sciences Group Inc (SLS) investing.com - March 10 at 5:06 AM
	SELLAS Life Sciences Group, Inc.: SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships finanznachrichten.de - March 9 at 3:43 PM
	SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships globenewswire.com - March 8 at 8:00 AM
	SLS Mar 2024 4.000 put finance.yahoo.com - March 7 at 11:22 PM
	SELLAS Life Sciences Group, Inc. (SLS) finance.yahoo.com - March 1 at 3:52 PM
	SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference globenewswire.com - March 1 at 8:30 AM
	SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time globenewswire.com - February 29 at 8:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adamis Pharmaceuticals

NASDAQ:ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

Merrimack Pharmaceuticals

NASDAQ:MACK

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company in the United States. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Opiant Pharmaceuticals

NASDAQ:OPNT

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.

SELLAS Life Sciences Group

NASDAQ:SLS

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial